USSTOCK.TODAY
Market Closed
Log in Sign up

Processa Pharmaceuticals Inc(PCSA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

PCSA
PCSA
Processa Pharmaceuticals Inc
At close Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$1.69
-0.01 ▼ -0.59%
Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$1.69
+0.00 +0.00%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -65.36Insider Own ⓘ 14.79%Shs Outstand ⓘ 2.8MPerf Week ⓘ -8.15%
Market Cap ⓘ 0.00BForward P/E ⓘ -EPS next Y ⓘ -Insider Trans ⓘ 11.44%Shs Float ⓘ 2.4MPerf Month ⓘ -3.98%
Enterprise Value ⓘ 0.19BPEG ⓘ -EPS next Q ⓘ -Inst Own ⓘ 132.02%Short Float ⓘ 1.1%Perf Quarter ⓘ -18.75%
Income ⓘ -0.19BP/S ⓘ -EPS this Y ⓘ -Inst Trans ⓘ 9.82%Short Ratio ⓘ 0.33Perf Half Y ⓘ -34.11%
Sales ⓘ 0.00BP/B ⓘ -EPS next 5Y ⓘ -ROA ⓘ -203.76%Short Interest ⓘ 0.03MPerf YTD ⓘ -41.32%
Book/sh ⓘ -64.82P/C ⓘ 0.03EPS past 3/5Y ⓘ 77% 61.77%ROE ⓘ -207.72%52W High ⓘ -80.97% ($8.88)Perf Year ⓘ -75.74%
Cash/sh ⓘ 64.51P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -107.22%52W Low ⓘ 62.34% ($1.04)Perf 3Y ⓘ -99.21%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ -92.15%Gross Margin ⓘ -Volatility(W/M) ⓘ 7.6% 8.15%Perf 5Y ⓘ -99.94%
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -Oper. Margin ⓘ -ATR (14) ⓘ 0.15Perf 10Y ⓘ -99.96%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 97.7EPS Q/Q ⓘ -3306.47%Profit Margin ⓘ -RSI (14) ⓘ 41.23Recom ⓘ 2
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 97.7Sales Q/Q ⓘ -SMA20 ⓘ -8.1% ($1.84)Beta ⓘ 1.22Target Price ⓘ $25
Payout ⓘ -Debt/Eq ⓘ 0Earnings ⓘ -SMA50 ⓘ -5.35% ($1.79)Rel Volume ⓘ 0.5Prev Close ⓘ $1.7
Employees ⓘ 12LT Debt/Eq ⓘ 0EPS/Sales Surpr. ⓘ -13.64% -SMA200 ⓘ -25.72% ($2.28)Avg Volume(3M) ⓘ 0.08MPrice ⓘ $1.69
IPO ⓘ 2013/11/21Option/Short ⓘ No/YesTrades ⓘ 285Volume ⓘ 39,187Change ⓘ -0.59%
Company
PCSA PCSAProcessa Pharmaceuticals Inc | NASD | Biotechnology Deep dive

🧬 Processa Pharmaceuticals () is a clinical-stage biopharma specializing in developing 'Next Generation Cancer (NGC)' therapies by modifying the metabolism and distribution of already FDA-approved anticancer drugs to improve safety and efficacy. Its lead asset, PCS6422 (NGC-Cap), is in Phase 2 for metastatic breast cancer, while irinotecan-based PCS11T (NGC-Iri) is in preclinical development, reflecting the company's strategy of "upgrading" existing classes of anticancer drugs.

Quote

Over the past 1 year, on the lower side

81% below its 1-year high.

Now $1.69
52w low$1.0452w high$8.88
52W Range8%
Volume ⓘ 39,187

Traded less than usual. That is 50% of its average volume.

B
Overall · fairly good
We judged 4 of the 8 questions below. 2 rate excellent and 2 need caution.
No data for growth, valuation, outlook, dividends, or not applicable.
ETFs holding this stock 1 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #543 of 598 in the industry

Based on market cap of $5M.

FAQ

FAQ

What kind of company is PCSA?

PCSA belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of PCSA?

The market cap of PCSA is approximately $5M, ranking 5,576 within its sector.

What is the 52-week high and low for PCSA?

PCSA has recorded a 52-week high of $8.88 and a low of $1.04.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels